Related references
Note: Only part of the references are listed.Disease-modifying properties of long-term lithium treatment for amnestic mild cognitive impairment: randomised controlled trial
Orestes V. Forlenza et al.
BRITISH JOURNAL OF PSYCHIATRY (2011)
Combined Treatment with the Mood Stabilizers Lithium and Valproate Produces Multiple Beneficial Effects in Transgenic Mouse Models of Huntington's Disease
Chi-Tso Chiu et al.
NEUROPSYCHOPHARMACOLOGY (2011)
GSK3 and Alzheimer's disease: facts and fiction
Anna Kremer et al.
FRONTIERS IN MOLECULAR NEUROSCIENCE (2011)
The FAS gene, brain volume, and disease progression in Alzheimer's disease
Deniz Erten-Lyons et al.
ALZHEIMERS & DEMENTIA (2010)
PH domain leucine-rich repeat protein phosphatase 1 contributes to maintain the activation of the PI3K/Akt pro-survival pathway in Huntington's disease striatum
A. Saavedra et al.
CELL DEATH AND DIFFERENTIATION (2010)
NFAT/Fas signaling mediates the neuronal apoptosis and motor side effects of GSK-3 inhibition in a mouse model of lithium therapy
Raquel Gomez-Sintes et al.
JOURNAL OF CLINICAL INVESTIGATION (2010)
GSK3 signalling in neural development
Eun-Mi Hur et al.
NATURE REVIEWS NEUROSCIENCE (2010)
FADD: a regulator of life and death
Lea Tourneur et al.
TRENDS IN IMMUNOLOGY (2010)
GSK3 inhibitors show benefits in an Alzheimer's disease (AD) model of neurodegeneration but adverse effects in control animals
Shuxin Hu et al.
NEUROBIOLOGY OF DISEASE (2009)
Non-apoptotic functions of caspase-8
Jonathan Maelfait et al.
BIOCHEMICAL PHARMACOLOGY (2008)
Identification of an antiapoptotic protein complex at death receptors
M. Sun et al.
CELL DEATH AND DIFFERENTIATION (2008)
A feasibility and tolerability study of lithium in Alzheimer's disease
Alastair Macdonald et al.
INTERNATIONAL JOURNAL OF GERIATRIC PSYCHIATRY (2008)
Death receptor Fas (CD95) signaling in the central nervous system: tuning neuroplasticity?
Arno Reich et al.
TRENDS IN NEUROSCIENCES (2008)
Molecular neurobiology of bipolar disorder: a disease of 'mood-stabilizing neurons'?
Tadafumi Kato
TRENDS IN NEUROSCIENCES (2008)
The GSK3 hypothesis of Alzheimer's disease
Claudie Hooper et al.
JOURNAL OF NEUROCHEMISTRY (2008)
Neuronal apoptosis and reversible motor deficit in dominant-negative GSK-3 conditional transgenic mice
Raquel Gomez-Sintes et al.
EMBO JOURNAL (2007)
UP inhibits LTD in the hippocampus via regulation of GSK3β
Stephane Peineau et al.
NEURON (2007)
Glycogen synthase kinase-3 inhibition is integral to long-term potentiation
Claudie Hooper et al.
EUROPEAN JOURNAL OF NEUROSCIENCE (2007)
Glycogen synthase kinase-3 (GSK3) in psychiatric diseases and therapeutic interventions
Richard S. Jope et al.
CURRENT DRUG TARGETS (2006)
Role of glycogen synthase kinase-3 in insulin resistance and type 2 diabetes
Erik J. Henriksen et al.
CURRENT DRUG TARGETS (2006)
Targeting glycogen synthase kinase-3 in the CNS: Implications for the development of new treatments for mood disorders
Todd D. Gould et al.
CURRENT DRUG TARGETS (2006)
The paradoxical pro- and anti-apoptotic actions of GSK3 in the intrinsic and extrinsic apoptosis signaling pathways
Eleonore Beurel et al.
PROGRESS IN NEUROBIOLOGY (2006)
Lithium in maintenance therapy for bipolar disorder
AH Young et al.
JOURNAL OF PSYCHOPHARMACOLOGY (2006)
Full motor recovery despite striatal neuron loss and formation of irreversible amyloid-like inclusions in a conditional mouse model of Huntington's disease
M Díaz-Hernández et al.
JOURNAL OF NEUROSCIENCE (2005)
The glamour and gloom of glycogen synthase kinase-3
RS Jope et al.
TRENDS IN BIOCHEMICAL SCIENCES (2004)
Convergent evidence for impaired AKT1-GSK3β signaling in schizophrenia
ES Emamian et al.
NATURE GENETICS (2004)
Gait dynamics in trisomic mice: quantitative neurological traits of Down syndrome
TG Hampton et al.
PHYSIOLOGY & BEHAVIOR (2004)
Pharmacological inhibitors of glycogen synthase kinase 3
L Meijer et al.
TRENDS IN PHARMACOLOGICAL SCIENCES (2004)
AR-A014418, a selective GSK-3 inhibitor, produces antidepressant-like effects in the forced swim test
TD Gould et al.
INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY (2004)
GSK3 inhibitors: Development and therapeutic potential
P Cohen et al.
NATURE REVIEWS DRUG DISCOVERY (2004)
Lithium facilitates apoptotic signaling induced by activation of the Fas death domain-containing receptor
L Song et al.
BMC NEUROSCIENCE (2004)
Fas and Fas Ligand are associated with neuritic degeneration in the AD brain and participate in β-amyloid-induced neuronal death
JH Su et al.
NEUROBIOLOGY OF DISEASE (2003)
GSK-3: tricks of the trade for a multi-tasking kinase
BW Doble et al.
JOURNAL OF CELL SCIENCE (2003)
Metalloproteinase shedding of Fas ligand regulates β-amyloid neurotoxicity
DW Ethell et al.
CURRENT BIOLOGY (2002)
Glycogen synthase kinase-3β inhibitors prevent cellular polyglutamine toxicity caused by the Huntington's disease mutation
J Carmichael et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2002)
Treatment research in bipolar disorder - Issues and recommendations
RJ Baldessarini
CNS DRUGS (2002)
The multifaceted roles of glycogen synthase kinase 3β in cellular signaling
CA Grimes et al.
PROGRESS IN NEUROBIOLOGY (2001)
Molecular targets of lithium action
CJ Phiel et al.
ANNUAL REVIEW OF PHARMACOLOGY AND TOXICOLOGY (2001)
Evidence for genetic linkage of Alzheimer's disease to chromosome 10q
L Bertram et al.
SCIENCE (2000)
Susceptibility locus for Alzheimer's disease on chromosome 10
A Myers et al.
SCIENCE (2000)
Apolipoprotein-E dependent role for the FAS receptor in early onset Alzheimer's disease:: finding of a positive association for a polymorphism in the TNFRSF6 gene
L Feuk et al.
HUMAN GENETICS (2000)
Requirement for glycogen synthase kinase-3β in cell survival and NF-κB activation
KP Hoeflich et al.
NATURE (2000)
Increased cerebrospinal fluid Fas (Apo-1) levels in Alzheimer's disease -: Relationship with IL-6 concentrations
M Martínez et al.
BRAIN RESEARCH (2000)
Share Paper
